|
|
A world first: Bionic eye transplant lets blind woman see
The Next Web
Share
   
Thirty years ago, 54-year-old Dianne Ashworth started going blind when she was diagnosed with a hereditary condition — retinitis pigmentosa. A few decades of scientific progress later, she was implanted with a bionic eye prototype at the Royal Victorian Eye and Ear Hospital in May. In July, it was switched on after she fully recovered from her surgery. Ashworth hasn't regained full sight, but for the first time, there's hope: The Australian now see flashes of light and shapes when researchers deliver electrical pulses to the device.
Related articles:
Woman receives Australia's first bionic eye implant (The Australian, subscription required)
Woman regains partial sign with bionic eye transplant (redOrbit)
More
 |
Identify Antibodies That May Compromise Graft Survival
- Detect Presence of Complement Fixing Antibodies
- Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!
FREE SAMPLE
For Research Use Only. Not for use in diagnostic procedures.
|
Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation
Clinical Transplantation
Share
The significance of donor-specific antibodies is not well known in the setting of pancreas transplantation. Since December 2009, researchers prospectively followed pancreas transplant patients with single-antigen-luminex-bead testing at one, two, three, six and then every six months for the first two years. From our data it appears that post-transplant DSA in pancreas allograft recipients may not impact the early-pancreatic allograft outcomes.
More
Test detects CMV in transplant patients
Renal & Urology News
Share
The Food and Drug Administration has granted premarket approval to a test that assesses a patient's viral load of cytomegalovirus, the most common and important viral infection in recipients of solid organ transplants. The fully automated COBAS AmpliPrep/COBAS TaqMan CMV Test, from Roche, is the first FDA-approved laboratory test for use in quantifying CMV DNA in human plasma specimens.
Related article:
Delayed CMV treatment may work best in new kidney (MedPage Today, subscription required)
More
T regulatory cell therapy in transplantation: Stability, localization and functional specialization
Current Opinion in Organ Transplantation (subscription required)
Share
Knowledge of how Tregs work in transplantation comes from studies that do not recapitulate how these cells will be used in humans. There is a need to develop better preclinical models to study how the in-vivo function of human Tregs can be optimized to ensure they can meet the challenge of inducing transplantation tolerance.
More
 |
Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors. more
|
Chronic renal outcome after living donor liver transplantation
Clinical Transplantation (subscription required)
Share
Chronic kidney disease is one of the common complications after deceased donor liver transplantation. Although the worldwide pressing shortage in deceased donors has directed attention to living donor liver transplantation, LDLT cohort data focusing on chronic renal dysfunction is limited.
More
Chylous ascites after liver transplantation: Incidence and risk factors
Liver Transplantation (subscription required)
Share
In a recent study, researchers evaluated the diagnosis, epidemiology, risk factors and treatment of chylous ascites developing after liver transplantation. Between 2002 and 2011, liver transplantation was performed 693 times in 631 patients at a clinic.
More
Why do most bone marrow transplant patients fall victim to graft-versus-host disease?
RedOrbit
Share
A team of scientists led by a bone marrow transplant researcher at Fred Hutchinson Cancer Research Center has shed new light on why most bone marrow transplant patients who receive tissue-matched cells from unrelated donors still suffer acute graft-versus-host disease. The answer appears to lie in the discovery of previously undetected genetic differences in the DNA of patients and unrelated marrow donors.
More
| PRESIDENT'S CORNER |
Roslyn Mannon, MD
Conversations with the President
In her latest blog post, AST President, Dr. Roslyn Mannon writes about formulating a Clinical Research Community of Practice. Read the blog.
|
|
New webcast on kidney-paired donation
AST
Share
Use your AST user login information to watch a free 30-minute webcast summarizing outcomes from the Kidney Paired Donation Consensus Conference held in March. Click here and log in on the left hand side of the page (disregard the $25 price displayed on the right hand side of the page, this is for non-members).
This webcast includes information on:
Alternative KPD allocation systems currently in use
Discussion of challenges unique to KPD in terms of donor evaluation, geography, financing, histocompatibility and implementation
Future directions for KPD allocation
More
Submit abstracts now for AST's Cutting Edge of Transplantation (CEOT) 2013 meeting
AST
Share
Not a clinical meeting, not a research meeting — simply the cutting edge of both. "B Cells from Bedside to Bench to Bedside: A Comprehensive Look at B Cells and Antibodies in Transplantation," will be held Feb. 14-16, 2013 in Phoenix, at the Sheraton Wild Horse Pass.
AST's first Cutting Edge of Transplantation (CEOT) meeting is a multi-expert view of the most important clinical and research problems in transplantation. Integrated clinical transplant and basic science talks define best approaches to management and research questions.
Abstract submission is now open. Clinical, basic and translational abstracts related to the meeting topic will be considered. Submit as many as you'd like before the Oct. 31 deadline.
Join clinical and basic science experts to address key management and research questions: What is the state of the field and the challenges to successfully transplanting sensitized patients? How does the immunobiology of B cells, plasma cells and antibody inform these challenges to clinical practice and suggest solutions? What are the best desensitization protocols and alternative therapies and their short- and long-term outcomes? Where are we in 'precision diagnosis' and continued monitoring of antibody-mediated rejection (AMR)?
Valentine's Day with AST: CEOT is about the joy of discovery. On Valentine's Day 2013, share that joy and discover the wild beauty of the desert with your loved one. Let the spirit of this ancient land breathe new energy into your lives together in a spectacular setting.
Tired of having to remember multiple passwords?
AST
Share
Did you know that you can access your American Journal of Transplantation (AJT) subscription directly through the AST website?
Simply visit, www.a-s-t.org and log in with your username and password. Then click on the "Access Your AJT Subscription" link in the AJT section on the home page (towards the lower left-hand side of the page), or visit www.a-s-t.org/journal. This is a simpler way to access your subscription, without having to remember a separate password for the Wiley Online Library.
Should you have any questions, please do not hesitate to contact the AST home office via email at info@a-s-t.org or phone 856-439-9986.
|
|
|
Mobile version
